Targeting LIN28: a new hope in prostate cancer theranostics.

Abstract

The mortality and morbidity rates for prostate cancer have recently increased to alarming levels, rising higher than lung cancer. Due to a lack of drug targets and molecular probes, existing theranostic techniques are limited. Human LIN28A and its paralog LIN28B overexpression are associated with a number of tumors resulting in a remarkable increase in cancer aggression and poor prognoses. The current review aims to highlight recent work identifying the key roles of LIN28A and LIN28B in prostate cancer, and to instigate further preclinical and clinical research in this important area.

• Authors: Garima Shrivastava, Alaa Aa Aljabali, Seyed Hossein Shahcheraghi, Marzieh Lotfi, Madhur D Shastri, Shakti D Shukla, Dinesh K Chellappan, Niraj Kumar Jha, Krishnan Anand, Harish Dureja, Ritesh M Pabari, Vijay Mishra, Abdulmajeed G Almutary, Abdullah M Alnuqaydan, Nitin Charbe, Parteek Prasher, Poonam Negi, Rohit Goyal, Kamal Dua, Gaurav Gupta, Ángel Serrano-Aroca, Bojlul Bahar, Debmalya Barh, Pritam Kumar Panda, Kazuo Takayama, Kenneth Lundstorm, Paul McCarron, Hamid Bakshi, Murtaza M Tambuwala
• Journal: Future oncology (London, England) (Future Oncol) Vol. 17 Issue 29 Pg. 3873-3880 (Oct 2021) ISSN: 1744-8301 [Electronic] England
• PMID: 34263659 (Publication Type: Journal Article, Review)

Chemical References

• LIN28B protein, human
• RNA-Binding Proteins

Topics

• Humans
• Male
• Molecular Targeted Therapy
• Precision Medicine
• Prostatic Neoplasms (pathology, therapy)
• RNA-Binding Proteins (metabolism)